Fairvalue-Calculator Fairvalue-Calculator
EN DE

Adaptimmune Therapeutics plc (ADAPY) Fair Value & Analysis

Healthcare · US · Market cap $9.5M

Price$0.0410
Fair Value$0.0365
Upside-11.0%
Quality92/100
Evidence: Low Range $0.0324 – $0.0406

Fair value as of: Jun 26, 2026

Analysis

Adaptimmune Therapeutics plc (ADAPY) currently trades at $0.0410, while our model-based Fair Value estimate is $0.0365 — implying the stock looks roughly 11.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Adaptimmune Therapeutics plc (ADAPY) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0365 versus a price of $0.0410 — about −11% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ADAPY?
Our 21-model fair value for Adaptimmune Therapeutics plc is $0.0365 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0410.
What is the quality score of ADAPY?
Adaptimmune Therapeutics plc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.